Ligands of the CB2 cannabinoid receptors augment activity of the conventional antidepressant drugs in the behavioural tests in mice

2020
journal article
article
10
dc.abstract.enAlthough a lot of information can be found on the specific dual role of the endocannabinoid system in the emotional-related responses, little is known whether stimulation or inhibition of the cannabinoid (CB) receptors may affect the activity of the frequently prescribed antidepressant drugs. Our interests have been particularly focused on the potential influence of the CB$_{2}$ receptors, as the ones whose central effects are relatively poorly documented when compared to the central effects of the CB$_{1}$ receptors. Therefore, we evaluated the potential interaction between the CB$_{2}$ receptor ligands (i.e., JWH133 - CB$_{2}$ receptor agonist and AM630 - CB$_{2}$ receptor inverse agonist) and several common antidepressant drugs that influence the monoaminergic system (i.e., imipramine, escitalopram, reboxetine). In order to assess the antidepressant-like effects we used two widely recognized behavioural tests, the mouse forced swim test (FST) and the tail suspension test (TST). Brain concentrations of the tested antidepressants were evaluated by the HPLC method. Intraperitoneal co-administration of per se ineffective doses of JWH133 (0.25 mg/kg) or AM630 (0.25 mg/kg) with imipramine (15 mg/kg), escitalopram (2 mg/kg), and reboxetine (2.5 mg/kg) significantly shortened the immobility time of mice in the FST and the TST, whereas it did not disturb their spontaneous locomotor activity. Furthermore, the brain levels of antidepressants were not changed. Summarizing, the results of the present study revealed that both activation and inhibition of the CB2 receptor function have a potential to strengthen the antidepressant activity of drugs targeting the monoaminergic system. Most probably, the described interaction has a pharmacodynamic background.pl
dc.affiliationWydział Farmaceutyczny : Zakład Farmakokinetyki i Farmacji Fizycznejpl
dc.cm.date2020-12-02
dc.cm.id96614
dc.contributor.authorPoleszak, Ewapl
dc.contributor.authorWośko, Sylwiapl
dc.contributor.authorSławińska, Karolinapl
dc.contributor.authorWyska, Elżbieta - 133861 pl
dc.contributor.authorSzopa, Aleksandrapl
dc.contributor.authorSobczyński, Janpl
dc.contributor.authorWróbel, Andrzejpl
dc.contributor.authorDoboszewska, Urszulapl
dc.contributor.authorWlaź, Piotrpl
dc.contributor.authorSzponar, Jarosławpl
dc.contributor.authorSkałecki, Piotrpl
dc.contributor.authorSerefko, Annapl
dc.date.accessioned2020-12-02T10:07:52Zpl
dc.date.available2020-12-02T10:07:52Zpl
dc.date.issued2020pl
dc.date.openaccess0
dc.description.accesstimew momencie opublikowania
dc.description.points100pl
dc.description.versionostateczna wersja wydawcy
dc.description.volume378pl
dc.identifier.articleid112297pl
dc.identifier.doi10.1016/j.bbr.2019.112297pl
dc.identifier.eissn1872-7549pl
dc.identifier.issn0166-4328pl
dc.identifier.projectROD UJ / OPpl
dc.identifier.urihttps://ruj.uj.edu.pl/xmlui/handle/item/256374
dc.languageengpl
dc.language.containerengpl
dc.rightsUdzielam licencji. Uznanie autorstwa 4.0 Międzynarodowa*
dc.rights.licenceCC-BY
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/legalcode.pl*
dc.share.typeinne
dc.subject.enJWH133pl
dc.subject.enAM630pl
dc.subject.enImipraminepl
dc.subject.enReboxetinepl
dc.subject.enEscitaloprampl
dc.subject.enAntidepressant activitypl
dc.subtypeArticlepl
dc.titleLigands of the CB2 cannabinoid receptors augment activity of the conventional antidepressant drugs in the behavioural tests in micepl
dc.title.journalBehavioural Brain Researchpl
dc.typeJournalArticlepl
dspace.entity.typePublication
dc.abstract.enpl
Although a lot of information can be found on the specific dual role of the endocannabinoid system in the emotional-related responses, little is known whether stimulation or inhibition of the cannabinoid (CB) receptors may affect the activity of the frequently prescribed antidepressant drugs. Our interests have been particularly focused on the potential influence of the CB$_{2}$ receptors, as the ones whose central effects are relatively poorly documented when compared to the central effects of the CB$_{1}$ receptors. Therefore, we evaluated the potential interaction between the CB$_{2}$ receptor ligands (i.e., JWH133 - CB$_{2}$ receptor agonist and AM630 - CB$_{2}$ receptor inverse agonist) and several common antidepressant drugs that influence the monoaminergic system (i.e., imipramine, escitalopram, reboxetine). In order to assess the antidepressant-like effects we used two widely recognized behavioural tests, the mouse forced swim test (FST) and the tail suspension test (TST). Brain concentrations of the tested antidepressants were evaluated by the HPLC method. Intraperitoneal co-administration of per se ineffective doses of JWH133 (0.25 mg/kg) or AM630 (0.25 mg/kg) with imipramine (15 mg/kg), escitalopram (2 mg/kg), and reboxetine (2.5 mg/kg) significantly shortened the immobility time of mice in the FST and the TST, whereas it did not disturb their spontaneous locomotor activity. Furthermore, the brain levels of antidepressants were not changed. Summarizing, the results of the present study revealed that both activation and inhibition of the CB2 receptor function have a potential to strengthen the antidepressant activity of drugs targeting the monoaminergic system. Most probably, the described interaction has a pharmacodynamic background.
dc.affiliationpl
Wydział Farmaceutyczny : Zakład Farmakokinetyki i Farmacji Fizycznej
dc.cm.date
2020-12-02
dc.cm.id
96614
dc.contributor.authorpl
Poleszak, Ewa
dc.contributor.authorpl
Wośko, Sylwia
dc.contributor.authorpl
Sławińska, Karolina
dc.contributor.authorpl
Wyska, Elżbieta - 133861
dc.contributor.authorpl
Szopa, Aleksandra
dc.contributor.authorpl
Sobczyński, Jan
dc.contributor.authorpl
Wróbel, Andrzej
dc.contributor.authorpl
Doboszewska, Urszula
dc.contributor.authorpl
Wlaź, Piotr
dc.contributor.authorpl
Szponar, Jarosław
dc.contributor.authorpl
Skałecki, Piotr
dc.contributor.authorpl
Serefko, Anna
dc.date.accessionedpl
2020-12-02T10:07:52Z
dc.date.availablepl
2020-12-02T10:07:52Z
dc.date.issuedpl
2020
dc.date.openaccess
0
dc.description.accesstime
w momencie opublikowania
dc.description.pointspl
100
dc.description.version
ostateczna wersja wydawcy
dc.description.volumepl
378
dc.identifier.articleidpl
112297
dc.identifier.doipl
10.1016/j.bbr.2019.112297
dc.identifier.eissnpl
1872-7549
dc.identifier.issnpl
0166-4328
dc.identifier.projectpl
ROD UJ / OP
dc.identifier.uri
https://ruj.uj.edu.pl/xmlui/handle/item/256374
dc.languagepl
eng
dc.language.containerpl
eng
dc.rights*
Udzielam licencji. Uznanie autorstwa 4.0 Międzynarodowa
dc.rights.licence
CC-BY
dc.rights.uri*
http://creativecommons.org/licenses/by/4.0/legalcode.pl
dc.share.type
inne
dc.subject.enpl
JWH133
dc.subject.enpl
AM630
dc.subject.enpl
Imipramine
dc.subject.enpl
Reboxetine
dc.subject.enpl
Escitalopram
dc.subject.enpl
Antidepressant activity
dc.subtypepl
Article
dc.titlepl
Ligands of the CB2 cannabinoid receptors augment activity of the conventional antidepressant drugs in the behavioural tests in mice
dc.title.journalpl
Behavioural Brain Research
dc.typepl
JournalArticle
dspace.entity.type
Publication
Affiliations

* The migration of download and view statistics prior to the date of April 8, 2024 is in progress.

Views
9
Views per month
Views per city
Ashburn
3
Wroclaw
2
Dublin
1
Krakow
1
Warsaw
1
Downloads
wyska_et-al_ligands_of_the_cb2_cannabinoid_receptors_augment_activity_2020.pdf
16